Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P56539: Variant p.Ala46Thr

Caveolin-3
Gene: CAV3
Feedback?
Variant information Variant position: help 46 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Alanine (A) to Threonine (T) at position 46 (A46T, p.Ala46Thr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and hydrophobic (A) to medium size and polar (T) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In RMD2; decreased surface expression of the CAV3 protein. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 46 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 151 The length of the canonical sequence.
Location on the sequence: help NRDPKNINEDIVKVDFEDVI A EPVGTYSFDGVWKVSYTTFT The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         NRDPKNINEDIVKVDFEDVIAEPVGTYSFDGVWKVSYTTFT

Mouse                         NRDPKNINEDIVKVDFEDVIAEPEGTYSFDGVWKVSFTTFT

Rat                           NRDPKNINEDIVKVDFEDVIAEPEGTYSFDGVWRVSYTTFT

Pig                           NRDPKNINEDIVKVDFEDVIAEPVGTYSFDGVWKVSYTTFT

Bovine                        NRDPKNINEDIVKVDFEDVIAEPVGTYSFDGVWKVSYTTFT
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 151 Caveolin-3
Topological domain 1 – 83 Cytoplasmic
Cross 38 – 38 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO3)



Literature citations
Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy.
Herrmann R.; Straub V.; Blank M.; Kutzick C.; Franke N.; Jacob E.N.; Lenard H.-G.; Kroger S.; Voit T.;
Hum. Mol. Genet. 9:2335-2340(2000)
Cited for: VARIANT RMD2 THR-46; Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease.
Betz R.C.; Schoser B.G.H.; Kasper D.; Ricker K.; Ramirez A.; Stein V.; Torbergsen T.; Lee Y.-A.; Nothen M.M.; Wienker T.F.; Malin J.-P.; Propping P.; Reis A.; Mortier W.; Jentsch T.J.; Vorgerd M.; Kubisch C.;
Nat. Genet. 28:218-219(2001)
Cited for: INVOLVEMENT IN RMD2; VARIANTS RMD2 GLN-27; THR-46; VAL-46 AND LEU-105; CHARACTERIZATION OF VARIANT RMD2 THR-46; Molecular and muscle pathology in a series of caveolinopathy patients.
Fulizio L.; Chiara-Nascimbeni A.; Fanin M.; Piluso G.; Politano L.; Nigro V.; Angelini C.;
Hum. Mutat. 25:82-89(2005)
Cited for: VARIANT HYPCK GLN-27; VARIANT RMD2 THR-46; VARIANT MPDT LYS-33; VARIANT MYOPATHY ARG-61;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.